JP6602761B2 - 眼科用デバイス - Google Patents

眼科用デバイス Download PDF

Info

Publication number
JP6602761B2
JP6602761B2 JP2016531690A JP2016531690A JP6602761B2 JP 6602761 B2 JP6602761 B2 JP 6602761B2 JP 2016531690 A JP2016531690 A JP 2016531690A JP 2016531690 A JP2016531690 A JP 2016531690A JP 6602761 B2 JP6602761 B2 JP 6602761B2
Authority
JP
Japan
Prior art keywords
polymer
drug delivery
matrix core
polymer matrix
delivery device
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016531690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537370A (ja
Inventor
ジャン−マリー ラキック
ジャン−ミシェル フォワダール
Original Assignee
アイド ファーマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイド ファーマ filed Critical アイド ファーマ
Publication of JP2016537370A publication Critical patent/JP2016537370A/ja
Application granted granted Critical
Publication of JP6602761B2 publication Critical patent/JP6602761B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/005—Templates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2016531690A 2013-11-14 2014-11-14 眼科用デバイス Active JP6602761B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13192889.7 2013-11-14
EP13192889 2013-11-14
PCT/EP2014/074644 WO2015071427A1 (en) 2013-11-14 2014-11-14 Eye device

Publications (2)

Publication Number Publication Date
JP2016537370A JP2016537370A (ja) 2016-12-01
JP6602761B2 true JP6602761B2 (ja) 2019-11-06

Family

ID=49584627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016531690A Active JP6602761B2 (ja) 2013-11-14 2014-11-14 眼科用デバイス

Country Status (17)

Country Link
US (1) US9999595B2 (enExample)
EP (2) EP3566693B1 (enExample)
JP (1) JP6602761B2 (enExample)
KR (1) KR20160085870A (enExample)
CN (1) CN105792812B (enExample)
AU (1) AU2014350095B9 (enExample)
BR (1) BR112016010638B1 (enExample)
CA (1) CA2929684C (enExample)
CL (1) CL2016001160A1 (enExample)
EA (1) EA032183B1 (enExample)
ES (2) ES2864274T3 (enExample)
HK (1) HK1223271A1 (enExample)
IL (1) IL245405A0 (enExample)
MA (1) MA39111A1 (enExample)
MX (1) MX2016006142A (enExample)
TN (1) TN2016000162A1 (enExample)
WO (1) WO2015071427A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10507101B2 (en) 2014-10-13 2019-12-17 W. L. Gore & Associates, Inc. Valved conduit
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
US11351058B2 (en) 2017-03-17 2022-06-07 W. L. Gore & Associates, Inc. Glaucoma treatment systems and methods
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
US11298262B2 (en) 2018-07-23 2022-04-12 The Regents Of The University Of Colorado, A Body Corporate Ophthalmic device for drug delivery
AU2019333136B2 (en) 2018-08-29 2022-11-17 W. L. Gore & Associates, Inc. Drug therapy delivery systems and methods
US11678983B2 (en) 2018-12-12 2023-06-20 W. L. Gore & Associates, Inc. Implantable component with socket
EP3990042A4 (en) 2019-06-27 2023-07-19 Layerbio, Inc. METHODS AND SYSTEMS FOR RELEASING EYE DEVICES
US11399977B2 (en) 2020-06-04 2022-08-02 SpyGlass Pharma, Inc. Ophthalmic implant system for drug delivery
US12472148B2 (en) 2021-04-26 2025-11-18 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
US20230149298A1 (en) * 2021-11-17 2023-05-18 Celanese Eva Performance Polymers Llc Implantable Device for Treating an Inflammatory Eye Condition
CN114224822B (zh) * 2022-01-28 2023-07-14 复旦大学附属眼耳鼻喉科医院 一种眼部缓释给药植入物及其制造方法
EP4233836B1 (en) * 2022-02-24 2024-11-06 Eyed Pharma Intraocular drug delivery device comprising an eyelet
US12285357B2 (en) 2022-07-22 2025-04-29 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
WO2024020505A2 (en) * 2022-07-22 2024-01-25 SpyGlass Pharma, Inc. Intraocular drug delivery systems and methods of use
CN121038751A (zh) * 2023-06-27 2025-11-28 博爱视觉有限责任公司 一种眼球植入体
KR102783540B1 (ko) * 2023-12-22 2025-03-17 조선대학교산학협력단 인공수정체 및 이의 제조방법

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3618604A (en) 1969-06-09 1971-11-09 Alza Corp Ocular insert
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4718905A (en) * 1986-08-13 1988-01-12 Freeman Jerre M Haptic element using ion beam implantation for an intraocular lens
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5928282A (en) * 1997-06-13 1999-07-27 Bausch & Lomb Surgical, Inc. Intraocular lens
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
FR2787991B1 (fr) 1998-12-31 2001-05-25 Medicale De Prec S M P Sa Soc Dispositif pour traiter la presbytie ou autre affection oculaire
GB2399753B (en) * 2002-01-18 2006-04-19 Michael E Snyder Method of making a sustained release ophthalmological device
FR2844703B1 (fr) 2002-09-25 2005-07-08 Alain Nicolas Gilg Dispositif intraoculaire pour restaurer l'accommodation de l'oeil atteint de presbytie
US20090018650A1 (en) * 2003-06-19 2009-01-15 Boxer Wachler Brian S Ophthalmological zonular stretch segment for treating presbyopia
JP2008535847A (ja) * 2005-04-08 2008-09-04 サーモディクス，インコーポレイティド 網膜下に送達するための持続放出インプラント
WO2009140246A2 (en) * 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2334285A1 (en) * 2008-09-12 2011-06-22 Critical Pharmaceuticals Limited Improvements in the absorption of therapeutic agents across mucosal membranes or the skin
WO2010101758A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. Peri-corneal drug delivery device
BR112012025581A2 (pt) * 2010-04-06 2019-09-24 Allergan Inc implantes de reservatório de liberação sustentada para distribuição de fármaco intracameral

Also Published As

Publication number Publication date
CL2016001160A1 (es) 2017-03-17
BR112016010638B1 (pt) 2023-01-31
EP3566693A1 (en) 2019-11-13
US9999595B2 (en) 2018-06-19
IL245405A0 (en) 2016-06-30
AU2014350095B9 (en) 2019-09-12
EP3566693B1 (en) 2021-02-17
EP3068372B1 (en) 2019-05-08
US20160287513A1 (en) 2016-10-06
CA2929684C (en) 2022-02-22
EA032183B1 (ru) 2019-04-30
ES2740352T3 (es) 2020-02-05
ES2864274T3 (es) 2021-10-13
JP2016537370A (ja) 2016-12-01
AU2014350095B2 (en) 2019-08-29
EP3068372A1 (en) 2016-09-21
CN105792812B (zh) 2020-10-23
WO2015071427A1 (en) 2015-05-21
AU2014350095A1 (en) 2016-06-09
TN2016000162A1 (en) 2017-10-06
CN105792812A (zh) 2016-07-20
HK1223271A1 (zh) 2017-07-28
MA39111A1 (fr) 2017-04-28
BR112016010638A2 (enExample) 2017-08-08
MX2016006142A (es) 2016-12-09
KR20160085870A (ko) 2016-07-18
CA2929684A1 (en) 2015-05-21
EA201690967A1 (ru) 2016-10-31

Similar Documents

Publication Publication Date Title
JP6602761B2 (ja) 眼科用デバイス
US10881609B2 (en) Methods for treating eye disorders using ocular implants
US6991808B2 (en) Process for the production of sustained release drug delivery devices
CN101984745B (zh) 用于持续释放治疗药物的药物核心
JP2016127945A (ja) １つまたは複数の薬剤の徐放性送達
WO2016064959A1 (en) Two-layer ocular implant comprising a tyrosine kinase inhibitor
Gote et al. Ocular implants in the clinic and under clinical investigation for ocular disorders
Nagai et al. New Paradigm for Long-Acting Retinal Drug Delivery: An Unoprostone-Release Device for the Treatment of Retinitis Pigmentosa
JP2024531834A (ja) 眼科用デバイスおよび方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170920

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180806

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190417

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190729

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191009

R150 Certificate of patent or registration of utility model

Ref document number: 6602761

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250